• Progression Free Survival [ Time Frame: 2 years ]
  from date of inclusion to date of progression, relapse, or death from any cause
• Overall Survival [ Time Frame: 2 years ]
  from the date of inclusion to date of death, irrespective of cause
• Cardiac toxicity [ Time Frame: 2 years ]
  cardiotoxity Congestive heart failure with clinical symptoms, or no symptoms but an abnormal LVEF
• Adverse Events [ Time Frame: 2 years ]
  any unfavorable and unintended sign , symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure

• Drug: Cyclophosphamide
  750mg/m² ivgtt on day 1
  Other Name: CTX
• Drug: pegylated liposomal doxorubicin
  40mg/m² ivgtt on day 1
  Other Name: PLD
• Drug: Vincristine
  1.4mg/m²(Maximum 2 mg) ivgtt on day 1
  Other Name: VCR
• Drug: Prednisone
  Prednisone100mg/m² po on day1-5
  Other Name: PED
• Drug: Doxorubicin
  50mg/m² ivgtt on day 1
  Other Name: DOX

• Experimental: CDOP regimen
  cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) administered in 3 week cycles for 6 cycles.
  Interventions:

  • Drug: Cyclophosphamide
  • Drug: pegylated liposomal doxorubicin
  • Drug: Vincristine
  • Drug: Prednisone
• Active Comparator: CHOP regimen
  cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles.
  Interventions:

  • Drug: Cyclophosphamide
  • Drug: Vincristine
  • Drug: Prednisone
  • Drug: Doxorubicin

Inclusion Criteria:

1. Patients with histologically proven untreated peripheral T-cell lymphoma (include PTCL not otherwise specified（PTCL-NOS）, angioimmunoblastic T cell lymphoma（AITL）, anaplastic large cell lymphoma（ALCL）and other peripheral T-cell lymphoma(except NK/T cell lymphoma);
2. Males and females of 18 years of age to 75 years of age.
3. Eastern Cooperative Oncology Group (ECOG) performance status 0- 2.
4. At least 1 single size measurable lesions, CT or PET-CT scan shows more than 15mm.
5. Estimated survival time ≥ 6 months
6. Liver function: transaminases≤3×ULN，or transaminases≤3×ULN for liver metastasis，total bilirubin ≤1.5ULN，or total bilirubin ≤2.5ULN for Gilbert's syndrome
7. Renal function: serum creatinine ≤1.5×ULN or creatinine clearance ≥ 60 ml / min ( standard Cockcroft-Gault formula);
8. peripheral hemogram: WBC≥3.0×10^9/L, ANC≥1.5×10^9/L, Hb≥90g/L, PLT≥75×10^12/L.
9. Cardiac ultrasound LVEF≥55%;
10. New York Heart Association (NYHA) heart function classification is I grade;
11. sign informed consent.

Exclusion Criteria:

1. Patients with primary or secondary central nervous system lymphoma；
2. Serious heart disease, including but not limited to:

1)Significant ventricular arrhythmia or high degree atrioventricular block (Mobitz II or third degree atrioventricular block); 2) unstable angina; 3) clinically significant heart valve disease; 4) Electrocardiogram shows transmural myocardial infarction; 5) Uncontrollable hypertension; 3. interstitial pneumonia, allergic asthma or severe allergic medical history; 4.Patients with other malignancies in the past or now (except basal cell carcinoma, squamous-cell carcinoma or carcinoma in situs of cervix that has been adequately treated), 5.HIV antibody positivity; 6.Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable) 7.Pregnancy or lactation period 8.Patients with Organ transplantation 9.Patients with serious uncontroled acute infection 10.High doses of hormones are contraindicated, such as uncontrolled hyperglycemia, stomach ulcers or Mental illness, etc.

11.Patients with severe neurological or psychiatric history, including dementia or epilepsy 12.The researchers considered that patients are not suitable for the study